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Quantitative multi-parametric evaluation of
centrosome declustering drugs: centrosome
amplification, mitotic phenotype, cell cycle and death
A Ogden1, A Cheng1, PCG Rida1, V Pannu1, R Osan2, R Clewley3 and R Aneja*,1
Unlike normal cells, cancer cells contain amplified centrosomes and rely on centrosome clustering mechanisms to form a
pseudobipolar spindle that circumvents potentially fatal spindle multipolarity (MP). Centrosome clustering also promotes low-
grade chromosome missegregation, which can drive malignant transformation and tumor progression. Putative ‘centrosome
declustering drugs’ represent a cancer cell-specific class of chemotherapeutics that produces a common phenotype of
centrosome declustering and spindle MP. However, differences between individual agents in terms of efficacy and phenotypic
nuances remain unexplored. Herein, we have developed a conceptual framework for the quantitative evaluation of centrosome
declustering drugs by investigating their impact on centrosomes, clustering, spindle polarity, cell cycle arrest, and death in
various cancer cell lines at multiple drug concentrations over time. Surprisingly, all centrosome declustering drugs evaluated in
our study were also centrosome-amplifying drugs to varying extents. Notably, all declustering drugs induced spindle MP, and the
peak extent of MP positively correlated with the induction of hypodiploid DNA-containing cells. Our data suggest acentriolar
spindle pole amplification as a hitherto undescribed activity of some declustering drugs, resulting in spindle MP in cells that may
not have amplified centrosomes. In general, declustering drugs were more toxic to cancer cell lines than non-transformed ones,
with some exceptions. Through a comprehensive description and quantitative analysis of numerous phenotypes induced by
declustering drugs, we propose a novel framework for the assessment of putative centrosome declustering drugs and describe
cellular characteristics that may enhance susceptibility to them.
Cell Death and Disease (2014) 5, e1204; doi:10.1038/cddis.2014.164; published online 1 May 2014
Subject Category: Cancer
Solid and hematological cancers often exhibit numerical
centrosome amplification (CA), the presence of more than
one centrosome before S phase or two thereafter, a rarity in
normal human tissues.1 CA correlates positively with malig-
nancy, suggesting that CA benefits cancer cells. Indeed, CA
induced tumor formation andmetastasis in aDrosophila larval
brain transplantation assay.2 Moreover, CA may promote
metastasis by enhancing directional migration and invasion.3
Nonetheless, CA also poses a liability to cancer cells. CAmay
result in potentially lethal mitotic spindle MP. MP can induce
death following prolonged mitotic arrest (MA) or cause
multipolar mitosis, resulting in daughter cells sustaining an
intolerable degree of aneuploidy.4,5 In order to escape these
calamitous fates, cancer cells employ centrosome clustering
mechanisms to assemble a pseudo-bipolar mitotic spindle.6–8
Centrosome clustering not only circumvents death but also
promotes low-grade chromosomemissegregation, whichmay
drive tumor evolution.9,10
Various factors are critical for centrosome clustering, such
as cortical actin, the spindle assembly checkpoint (SAC), cell
adhesion and polarity regulators, the Ndc80 microtubule-
kinetochore attachment complex, augmin complex members,
and microtubule motors (e.g., dynein and HSET).11–14
Inhibition of the kinesin-14 HSET has attracted attention
lately because it causes death selectively in cancer cells with
supernumerary centrosomes.11 Based on these promising
findings, two HSET inhibitors have been developed
recently.15,16 Inhibitors of centrosome clustering are selective
for cancer cells because most healthy adult human cells do
not exhibit CA, precluding their dependence on clustering
mechanisms.6,17 Consequently, putative centrosome declus-
tering agents have emerged as promising anticancer drugs.
These agents include griseofulvin (GF), noscapine (Nos), and
Nos derivatives (e.g., brominated noscapine (BN) and
reduced BN (RBN)), all of which modulate microtubule
dynamicity, as well as the phenanthrene-derived poly(ADP-
ribose) polymerase inhibitor, PJ-34 (PJ).
Like traditional spindle poisons, declustering drugs are
known to cause G2/M phase arrest (Nos,18 BN,18 RBN,19
GF,20 PJ21). Spindle poisons induce MA by perturbing
microtubule attachment to kinetochores, thereby activating
the SAC.22 The SAC prevents cyclin B1 degradation, resulting
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in sustained MA.23 The fates of spindle poison-treated,
mitotically arrested cells are thought to be governed by two
competing pathways: one that induces apoptosis in mitosis
(via caspase-dependent mechanisms) and another that
induces mitotic exit (via progressive degradation of
cyclin B1).22,24 Mitotic exit may culminate in apoptosis in
the subsequent interphase or may permit cell survival.25
Nevertheless, controversy surrounds the role of MA in
inducing apoptosis. Specifically, it remains unclear which
factors – the extent, onset, and/or duration of MA – are critical
for inducing apoptosis.22,25
Despite their common ability to induce MA, declustering
agents differ in their clinical indications and molecular
targets. GF is an antifungal and Nos is an antitussive,
both with different binding sites on microtubules, whereas
PJ is a phenanthrene-derived poly(ADP-ribose) polymerase
inhibitor with no known microtubule-binding capacity.
To date, no study has quantitatively compared the
declustering abilities of these diverse agents, which may
contrast given their pharmacologic differences. Furthermore,
these agents paradoxically are effective in cancer lines,
such as HeLa, PC3, and DLD-1 cells, which lack significant
CA26 (e.g., Nos and BN,18 GF,20,27 PJ,28 and RBN19). Unless
these drugs also induce CA (such as occurs with BN29
and RBN19), MP is perhaps being induced in such cell lines in
a centrosome declustering-independent manner. It was
recently demonstrated that inhibition of HSET can induce
MP via acentrosomal pole formation in cancer cells
irrespective of centrosome number.30 Thus, ‘acentrosomal
pole amplification’ represents a potential mechanism bywhich
declustering drugs might induce spindle MP in cancer cells
without CA.
Herein, we seek to quantitatively determine which of these
phenotypes – MA, CA, declustering, acentrosomal pole
amplification, and/or spindle MP – promote cancer cell death.
This information can provide a conceptual framework to aid
rational design of novel centrosome declustering drugs.
Results
Characterization of MA induced by centrosome
declustering drugs. To evaluate the impact of putative
declustering drugs on cell cycle progression and hypodi-
ploidy (o2N DNA content, which may indicate apoptotic
cells), MDA-MB-231 (231), PC3, and HeLa cells were treated
with different concentrations of declustering drugs, stained
with propidium iodide, labeled with anti-MPM2 antibody, and
then assessed by flow cytometry at multiple time points over
48 h. The chosen cell lines displayed different levels of
endogenous CA. 231 cells (mutant p53) exhibit high levels of
CA (B20–45%)11,31 compared with PC3 (p53 null) and HeLa
(wild-type but E6-inactivated p53), which have low basal
levels of CA. Consistent with previous reports, our data
showed that all drugs induced sustained MA (at least 2
mitotic cells compared with untreated control cultures) at the
concentrations indicated. The duration, highest degree, and
rapidity of onset of MA varied between drugs, drug
concentrations, and cell lines (Figures 1a and b). In general,
the maximum MA achieved was less pronounced in Nos- and
PJ-treated cells (Figures 1a and b). Drug-induced onset of
MA was corroborated by substantial increases in cyclin B1
levels in all cell lines (Figure 1c). For most cases, prolonged
MA (B24 h in duration) was followed by a substantial
increase in the subG1 population fraction (Figures 1a and
b). In all cases, we observed significant increases in cleaved
caspase-3 over controls (Figure 1c), suggesting apoptosis.
Instances wherein the subG1 fraction was elevated without
cleaved caspase-3 may either represent caspase-indepen-
dent cell death or the presence of hypodiploid cells whose
fate is unclear. In general, we found no consistent associa-
tions between the extent, duration, or timing of MA within
drugs or across cell lines (detailed in the Supplementary
Text, Supplementary Figure 1, and Supplementary Tables 1
and 2). Altogether, although centrosome declustering drugs
induced MA, significant differences existed in the (i) extents
and durations of MA, (ii) the size of the subG1 population,
(iii) the rapidity of the onset of MA and hypodiploidy, and
(iv) the extent to which hypodiploidy was accompanied by
caspase-dependent apoptosis (Figures 1a–c) even within a
given cell line.
Declustering drugs induce CA in cancer cell lines. As
RBN increases the expression of Plk4,19 a mediator of CA,
we investigated whether other declustering drugs affect the
expression of PLK4 along with two other mediators of CA,
Cyclin E and Aurora A. Interestingly, all the drugs we studied
increased PLK4, Cyclin E, and Aurora A compared with
untreated cultures (Figure 2a). Consequently, we assessed
CA in cultures treated with different concentrations of
declustering drugs for 6, 12, 18, or 24 h and untreated
controls via microscopy. Centrosomes were identified by
g-tubulin and centrin-2 colocalization at discrete foci.
Interestingly, all drugs tested induced CA in a statistically
significant manner in at least one cell type and drug
concentration (10 or 25 mM for all drugs except GF, which
was used at 25 and 50 mM). The average percentages of CA
over 24 h and the associated fold increases over controls are
shown in Figure 3 and Supplementary Figure 2, respectively.
The peak percent CA detected over 24 h is shown in
Supplementary Figure 4a (only statistically significant
(Po0.05) increases over control values are represented in
the figures, and a more detailed analysis is described in the
Supplementary Data). Representative confocal micrographs
of CA in interphase and mitotic cells, both control and drug
treated, are depicted in Figure 4. We did not find significant
correlations between the degree of CA (Figure 3a) and the
expression levels of PLK4, Cyclin E, and Aurora A (Figure 2).
Although declustering drugs might induce CA through path-
ways independent of these proteins, we conjecture that the
levels of these proteins required to induce CA may simply
vary between cell lines. Furthermore, many of the cells in
which CA was induced may have died, precluding their
quantitation. To determine whether the CA-inducing activity
of declustering drugs is restricted to cancer cells, we treated
two non-malignant cell lines, mammary fibrocystic (MCF10A)
cells and adult human dermal fibroblasts with these drugs.
We found that RBN, GF, and PJ did induce CA (for details,
see Supplementary Text, Supplementary Figures 3 and 4)
and cell death (Supplementary Table 3) in these cell lines to
varying extents. In summary, all the centrosome declustering
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drugs in our study were also centrosome-amplifying drugs,
depending on the cell line and drug concentration.
Effect of putative declustering agents on centrosome
declustering and spindle MP. Having identified that all the
declustering drugs in our study induce CA, we were
interested to quantitatively evaluate the extent to which they
induce MP and declustering. MP was considered low grade if
there were only 3 or 4 spindle poles and high grade if there
were Z5 poles. We found that all declustering drugs, at one
Figure 1 Mitotic arrest (MA) phenotypes observed upon treatment with putative centrosome declustering drugs. (a) SubG1 and mitotically arrested cell population
fractions with respect to time post-treatment with various putative declustering drugs. Declustering drugs included Nos, BN, RBN, PJ, and GF, all at 10 and 25mM except GF,
which was used at 25 and 50mM, and cell lines included 231, PC3, and HeLa. These cell lines demonstrated differential susceptibility to various agents depending on drug
concentration over the 48 h time period. In general, MA increased from 0 h to a peak near 24 h, followed by a decline in MA that coincided with increases in subG1 fractions.
Results are representative of three independent experiments. (b) Duration of MA and peak MA by maximum subG1 fraction. Drugs are ranked in order of increasing peak
subG1 from bottom to top along the y axis. The duration of MA (defined as the duration for which the mitotic population in drug-treated cells was greater than two times that in
control cells) is plotted along the x axis. The time at which peak MA occurred is illustrated as a red bar and the value of peak MA is listed to the right of the graph. In 231 cells, 10
BN did not cause any MA; therefore, no bar is plotted. For 10 Nos in 231 cells and 25 PJ in PC3 cells, MA was observed at only one time point and is depicted using a single red
bar. Some drugs produced a MA that then subsided and ultimately recurred, resulting in two bars being plotted, namely 50 GF in HeLa and PC3 cells. (c) Western blotting of
cell cycle-related proteins and caspase-3, a marker for apoptosis. To assess cell cycle progression following treatment with different declustering drugs (all at 25mM), cell
lysates were obtained at multiple time points over 48 h and immunoblotted for Cyclins E and B1. Increased levels of both cyclins compared with controls (0 h) were detected
across cell lines with variable expression patterns depending on the drug and cell line. To evaluate apoptosis, cleaved caspase-3 (C. Caspase-3) was immunoblotted and
eventual increases over controls were universally detected, typically by 24 h
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Figure 2 Centrosome declustering drug-induced changes in expression levels of markers of centrosome amplification. To evaluate the levels of some of
the well-established markers of CA upon treatment with declustering drugs at a concentration of 25 mM, the levels of PLK4, Cyclin E, and Aurora A were assessed by
western blotting, revealing eventual increases over untreated controls across cell lines. Increase in expression levels of PLK4 and Aurora A was generally rapid, often
appearing by 4 h. Levels tended to vary thereafter depending on the drug and cell line. Densitometry was performed to quantitate the changes in levels of CA markers
relative to b-actin over time, and the changes in actin-normalized expression levels over the time-course of the experiment are depicted graphically beneath each sets of blots.
As the Cyclin E blots revealed two closely placed bands (49 and 43 kDa) corresponding to the two spliced forms, the Cyclin E band intensity was generated as a sum of the two
band intensities
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or both concentrations, induced spindle MP in at least one
cell type above control levels (Figure 5a). Several of the
drugs induced acentrosomal or ‘acentriolar’ poles (wherein at
least one spindle pole stained positively for g-tubulin but not
centrin-2; Figure 5a), a phenotype not previously reported for
these particular drugs. This phenotype has been reported
following knockdown of HSET.30 We found that acentriolar
poles were more readily induced in HeLa than in PC3 or 231
cells (Figure 5a). The mechanism undergirding this pheno-
type is presently unknown. Some of the forces that tether
together supernumerary centrosomes may also preserve
spindle pole integrity,8 and our observations support that
hypothesis.
Next, we evaluated the extents to which these drugs
induced declustering. We found that the extent of total
declustering (the percentage of cells with amplified centro-
somes in which no centrosomes were clustered) induced by
all the drug regimens was the lowest in 231 cells, which have
higher endogenous CA (Figure 5b). By contrast, in HeLa and
PC3 cells, which have comparatively low levels of CA, a
majority of the amplified centrosomes were found to be totally
declustered (Figure 5b). For comparison, we assessed drug-
inducedMP, declustering, and acentrosomal pole formation in
non-malignant cell lines (for details, see Supplementary Text
and Data in Supplementary Figure 5a). We found that RBN,
GF, and PJ significantly induced MP over control levels,
and the supernumerary centrosomes induced tended be
declustered.
Ultimately, it appears that the drugs tested largely induce
spindle MP in a declustering-independent manner, at least in
the cancer cell lines tested here. Declustering drugs may
therefore prove effective in cancers regardless of the extent of
CA present.
Cross talk between drug-induced spindle MP, decluster-
ing, and drug efficacy. Next, we probed the associations
between drug-induced spindle MP, centrosome declustering,
and drug efficacy (subG1 extent) in order to identify the
phenotypes that contributed most to cell death. We used beta
regression (a statistical methodology more appropriate for
proportions data than linear regression when very low or high
percentages are observed) to analyze correlates of peak
subG1. For this technique, pseudoR2 (the squared correla-
tion of linear predictor and link-transformed response) is
reported rather than R2 as in linear regression, and it
indicates the goodness-of-fit of the model.
We discovered that across all drugs and cell lines, peak MP
significantly correlated with peak subG1 (P¼ 0.00840,
pseudoR2¼ 0.321), suggesting that generation of spindle
MP is a shared mechanism whereby declustering drugs
trigger cell death. Importantly, we found no significant
associations betweenCA and spindle MP, which corroborates
our finding that declustering drugs appear to induce spindle
MP by disrupting spindle pole and/or centrosome integrity,
which in some cases may also decluster centrosomes if an
excess is present. Within 231 cells, we found an even
stronger, positive correlation with a very good fit between
peak high-grade MP and peak subG1 (Figure 6ai; P¼ 0.006;
pseudoR2¼ 0.833), underscoring that a desirable attribute for
declustering drugs is the ability to induce high-grade rather
than low-gradeMP.We also found that a model including both
peak high-grade and low-grade MP together was better in
predicting peak subG1 (P¼ 0.001; pseudoR2¼ 0.860)
(Figure 6aii). Specifically, within this model, the prediction of
peak subG1 using peak high-grade MP was very highly
statistically significant (Po0.00001) and the beta coefficient
was positive, indicating a positive correlation between peak
high-grade MP and subG1 generation. The prediction of peak
subG1 using peak low-grade MP was very highly statistically
significant (P¼ 0.00001), and the beta coefficient was
negative, indicating a negative correlation between peak
low-grade MP and peak subG1. This finding is consistent with
the notion that high-grade MP engenders intolerably severe
aneuploidy that is likely to culminate in cell death, whereas
low-grade MP is more likely to be survivable and perhaps
advantageous to cancer cells. Clear trends were not
uncovered for centrosome declustering and subG1 across
drugs, although we cannot rule out its importance within
individual drugs, as the number of data points for peak subG1
was limiting.
In HeLa cells, peak MP (any grade) positively correlated
with peak subG1 (P¼ 0.0055; pseudoR2¼ 0.575; Figure 6ci).
Also, peak high-grade MP positively correlated somewhat
with peak subG1 (P¼ 0.028; pseudoR2¼ 0.271; Figure 6cii).
Notably, the peak acentriolar pole percentage positively
correlated with peak subG1 (P¼ 0.0023; pseudoR2¼ 0.600;
Figure 6ciii), so daughter HeLa cells without centrosomes
may be inviable. Indeed, based on the pseudoR2 value, peak
Figure 3 Average CA observed over 24 h and its relationship with peak subG1
for each drug treatment regimen. (a) Displayed are only statistically significant
(Po0.05) increases in average CA over controls. To calculate average CA, the sum
of percentage of (interphase or mitotic) cells showing CA at the 6, 12, 18, and 24 h
time points was divided by 4. (b) Depiction of the sum of average CA (interphase
plus mitotic) observed when 231 cells were treated with RBN, BN, and PJ,
compared with the treatment of HeLa and PC3 cells with the same three drugs
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acentriolar pole formation was superior to all other variables in
predicting peak subG1. Peak total declustering also positively
correlated with peak subG1 (P¼ 0.020; pseudoR2¼ 0.424;
Figure 6civ), strengthening the idea that more extensive
declustering kills more cancer cells.
In PC3 cells, wedid not find an association between peakMP
and peak subG1 across drugs. However, when we analyzed
the correlation between the average fold increase in CA
induction with peak subG1 percent, we found an interesting
trend. In PC3 cells, the proportion variable (peak subG1)
always lay within the 30–70% range and the other variable (fold
increase in CA) was continuous, so we implemented linear
regression for analysis. We found that the average fold
increase in CA in interphase positively correlated with peak
subG1 (P¼ 0.057; R2¼ 0.619; Figure 6b), suggesting that an
increase in CA may promote cell death.
We also analyzed the impact of treatment with declustering
drugs on spindle MP and subG1 induction in non-transformed
cells (for details, see Supplementary Data andSupplementary
Figure 6). In both MCF10A cells and human dermal
fibroblasts, peak MP positively correlated with peak subG1
(R2¼ 0.82 with P¼ 0.003 and R2¼ 0.89 with Po0.001,
respectively), suggesting that MP is also toxic to normal cells.
Discussion
Declustering of supernumerary centrosomes is a promising
chemotherapeutic approach that has recently come to light.
Centrosome declustering kills cancer cells with supernumerary
centrosomes while sparing normal cells, which rarely have
supernumerary centrosomes. To date, drugs that decluster
centrosomes have been grouped together given that they
share this ability; however, the precise mechanisms by which
they decluster centrosomes may differ and are unknown. It is
also unclear whether centrosome declustering is their sole, or
even primary, cellular activity. Ours is the first study to assess
the differential abilities of various declustering drugs to induce
MA, CA, MP, declustering, acentrosomal pole amplification,
and cell death in different malignant and non-malignant cell
lines. It would be valuable to have a framework to quantitatively
evaluate novel declustering drugs to improve their efficacy via
rational design. Our study lays the foundation for defining such
a framework, which could guide development of a next
generation of declustering drugs that are even more effective
in killing cancer cells and even less toxic to normal cells.
Centrosome declustering drugs induce MA followed by
death,19,27,28,32,33 and the duration of MA induced by some
microtubule-targeting drugs determines cell death after
mitotic exit.34 In concordance, we found that declustering
drugs induce MA, which is followed by a peak in the subG1
fraction. However, we also found great variability in the extent
ofMA, how rapidly its onset occurs, its duration, and the extent
of hypodiploidy generated between drugs and cell lines.
Differences were also apparent in the extent to which MA was
accompanied by the appearance of cleaved caspase-3, an
early marker of apoptosis. There were no clear associations
Figure 4 Representative confocal micrographs depicting centrosome amplification in controls and drug-treated cancer cells. (a) Interphase and (b) mitotic cells. Only
displayed are drug/cell line combinations in which statistically significant (Po0.05) fold increases in CA were found in mitotic cells, although all controls are shown regardless
of the extent of endogenous CA. Blue¼DNA, green¼microtubules, red¼ g-tubulin, and orange¼ centrin-2
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between peak MA, the duration of MA, and the timing of the
onset of MA with hypodiploidy or the various centrosome- and
spindle-related phenotypes we observed. These findings
convey the complexity of the cellular responses to these
drugs and suggest that the mechanisms of actions of these
drugs probably differ significantly.
A central finding of our study is that all the declustering
drugs upregulate PLK4, Cyclin E, andAurora A and induceCA
(Figure 2). This finding helps to clarify the seeming contra-
diction that centrosome declustering drugs are effective in cell
lines without much CA. Although it has been previously shown
that BN29 and RBN19 induce CA, no other studies to our
knowledge have demonstrated induction of CA by Nos, GF, or
PJ. It currently does not appear that the CA induced by these
drugs is coupled in any way to their declustering activity,
although further studies are needed to establish conclusively
whether these two activities are truly independent. Another
key finding from our study is that declustering drugs can
trigger ‘spindle pole amplification’ via two means, acting
separately or in concert: (i) genesis of acentriolar poles and
(ii) amplification and declustering of centrosomes, both of
which precipitate spindle MP.
SubG1 fraction (i.e., cell death) typically exceeded the
extent of CA, often by a wide margin (Figures 1 and 2,
Supplementary Table 3). Thus, CA and declustering alone
cannot explain the efficacy of these agents in the cell lines
examined. Many reports have demonstrated that MP can be
induced without centrosome declustering, such as through
spindle pole fragmentation, loss of microtubule anchoring at
the centrosome, PCM fragmentation, or centriole separation
in mitosis.35–38 Consequently, it is conceivable that ‘declus-
tering drugs’ are inducing MP in a centrosome declustering-
independent manner, such as by ‘declustering’ (defocusing)
spindle poles. For instance, treatment of HeLa cells with
50 mM GF (IC50¼ 35 mM27) for 24 h induced MP in 72% of
cells, even though we found that r4% of untreated controls
had CA, as others have found.26 We also discovered that
50 mMGF induced only a small increase in the extent of CA in
HeLa cells. Although the minority of multipolar cells with CA
did exhibit centrosome declustering in the presence of GF, the
Figure 5 (a) Peak MP and peak acentriolar pole formation induced by different declustering drugs in 231, HeLa, and PC3 cells. The maximum extents of MP induction of
high grades (5þ poles) and low grades (3–4 poles) and acentriolar pole formation (at least one pole without centrioles) across a 24-h period are given for all drugs. (b) Peak
CA and declustering of amplified centrosomes induced in 231, HeLa, and PC3 cells. The maximum extent of CA in mitosis over 24 h is depicted by the height of the bar. The
extent of total clustering (all centrosomes clustered at two poles), total declustering (all centrosomes separated to different poles), and partial declustering (one or more poles
with 2þ centrosomes) are given for that same time point
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majority of multipolar cells exhibited acentrosomal poles
without centrosome declustering, as they did not have extra
centrosomes that could be declustered. Nos, likewise, is
effective in cells without much endogenous CA, such as HeLa
(IC50¼ 25 mM32), and Nos frequently induced MP by generat-
ing acentrosomal poles (Figure 5a). Nos also induced further
CA in HeLa and PC3 cells and achieved nearly complete
declustering of these amplified centrosomes. Intriguingly,
although we confirmed that BN induced CA that closely
paralleled MP across cell lines (i.e., cells with CA were
generally the ones that were also MP; Figure 5a), we
discovered that the subG1 population exceeded the percen-
tage of cells with CA and/or MP. This finding suggests that
additional mechanisms may contribute to this drug’s antic-
ancer activity, even though CA and declustering appear to
operate as well. We also verified that RBN substantially
increases CA across cell lines but it often produces MP
spindles with one or more acentrosomal poles. Consequently,
like all the other putative centrosome declustering agents that
we studied, it does not seem that RBN is a ‘pure’ declustering
drug but may additionally disrupt spindle pole integrity or
otherwise cause spindle pole amplification, a downstream
consequence of which is centrosome declustering. Alto-
gether, it seems that MP itself, however it is generated
(whether via bona fide centrosome declustering or acentro-
somal spindle pole amplification), is a key driver of cell death
in 231 and HeLa cells, although CA may instead be
mechanistically involved in cell death in PC3 cells.
Ultimately, the diversity of previously unrecognized or
under-appreciated phenotypes uncovered by our study,
illustrated in Figure 7, raises a host of questions that represent
ample opportunities for future investigations. We have
discerned certain phenotypes that contribute to cell death,
which may guide rational development of these drugs or
formulation of synergistic drug combinations to enhance
chemotherapeutic efficacy. Altogether, our data highlight the
potential utility of centrosome declustering drugs in combatting
Figure 6 Correlates of peak subG1 percent within cell lines. (a) 231 cells, beta regression. (ai) In 231 cells, a clear trend was found for increasing peak MP of any grade
and peak subG1, which was highly statistically significant (P¼ 0.006; pseudoR2¼ 0.833). (aii) Furthermore, multiple regression using peak MP (high grade) and peak MP (low
grade) produced an even better, statistically significant fit (red line) compared with simulated values (P¼ 0.001; pseudoR2¼ 0.860). Within this model, both variables were
very highly statistically significant (Po0.0001), with peak high-grade MP showing a positive correlation and peak low-grade MP showing a negative correlation with peak
subG1 (based on the sign of the beta coefficients). (b) PC3 cells, linear regression. In these cells, the average fold increase in interphase CA shows some association with
peak subG1, which almost reached statistical significance and which produced a good fit (P¼ 0.057; R2¼ 0.619). (c) HeLa cells, beta regression. (ci) Increasing peak MP of
any grade was associated with peak subG1 (P¼ 0.0055; pseudoR2¼ 0.575), as was (cii). Increasing peak MP of high grade (P¼ 0.028; pseudoR2¼ 0.271). (ciii) Increasing
peak acentriolar pole formation (P¼ 0.0023; pseudoR2¼ 0.600), and (civ) peak total declustering (P¼ 0.020; pseudoR2¼ 0.424)
Figure 7 Diversity of phenotypes produced by putative centrosome declustering
drugs. One of the two central cells with bipolar spindles show normal centrosome
number (left cell) and the other one shows amplified centrosomes (right cell). Both
types of cells are susceptible to the declustering agents. For the cell without CA,
acentriolar pole formation (i.e., pole amplification or pole declustering) and MP (low- or
high-grade) may be induced. Alternatively, these agents may induce CA and permit
bona fide centrosome declustering to occur, partially or in total, with or without
acentriolar pole formation. For the cell with CA, genuine centrosome declustering may
occur, partially or in total, with or without acentriolar pole formation, and with or without
further CA. AC, acentriolar; DC, declustering; HGCA, high-grade CA; HGMP,
high-grade MP; LGCA, low-grade CA; LGMP, low-grade MP
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malignancy given that we found cancer cells are often more
susceptible to these agents than normal cells. Interestingly, we
uncovered that centrosome declustering drugsmay act partially
or primarily through spindle pole amplification. Declustering
may either operate in addition to spindle pole amplification or
may simply be a corollary of that process. Future studies are
awaited to further unravel the precise mechanisms by which
currently available declustering drugs operate to guide rational
design of novel members of this promising class.
Materials and Methods
Cell lines, cell culture, and drugs. HeLa, MDA-MB-231 (231), and PC3
cells were grown in medium (Dulbecco’s modified Eagle’s medium for HeLa and
231 cells, Roswell Park Memorial Institute medium for PC-3 cells; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% HyClone fetal bovine serum (Thermo
Scientific, Waltham, MA, USA) and maintained in a 95% CO2 atmosphere at
37 1C. BN and RBN were prepared as described previously.19,39 Nos, GF, and PJ
were purchased from Sigma (St. Louis, MO, USA). Cells were grown to B70%
confluence and treated with drug or vehicle (0.1% dimethyl sulfoxide) followed by
processing for flow cytometry, immunofluorescence confocal microscopy, or
immunoblotting as previously described.29
Immunofluorescence microscopy and western blotting. Primary
antibodies against g-tubulin, a-tubulin, and centrin-2 (Abcam, Cambridge, MA,
USA), Alexa 488-, 555-, and 647-conjugated secondary antibodies (Invitrogen),
and DAPI (Invitrogen) were diluted in 2% BSA/1 PBS 1 : 2000. Confocal
microscopy was performed using the Zeiss LSC 700 microscope (Oberkochen,
Germany) with a 1.4 NA oil-immersion lens, and image processing was performed
with Zen software (Oberkochen, Germany). For each drug at a particular
concentration (10, 25, or 50 mM) in a specific cell line (HeLa, 231, or PC3 cells),
200 cells in randomly selected fields were assessed for each time point (0, 12, 18,
and 24 h). If the number of mitotic cells out of 200 did not reach n¼ 50, additional
randomly selected mitotic cells were assessed until n¼ 50. The number of
interphase cells was never less than n¼ 133. Mitotic index was calculated for
each time point, and for both interphase and mitotic cells, the number of g-tubulin/
centrin-positive foci (i.e., centrosomes) in each cell was recorded. For mitotic cells,
the number of spindle poles was also recorded, along with the number of
centrosomes present, if any, at each pole. Western blotting was performed as
previously described40 using lysates from cells treated with 25mM drug for 0, 4, 8,
12, 16, 18, 20, 24, 28, 36, or 48 h.
Cell cycle analysis. The flow cytometric evaluation of cell cycle status was
done using FlowJo software (Ashland, OR, USA). After the treatment, cells were
harvested at different time intervals, washed twice with ice-cold PBS, and fixed in
70% ethanol for at least 24 h. Cell pellets were then washed with PBS and added
with 0.5 ml of RNase A (2mg/ml) and stained with MPM-2 primary mouse antibody
followed by Alexa-488 secondary antibody. In addition, 0.5 ml of propidium iodide
(0.1% with 0.6% Triton X-100 in PBS) was added for 45min in the dark followed by
analysis on a FACS Cantor flow cytometer (BD Canto, Franklin Lakes, NJ, USA).
Experiments were repeated in triplicate.
Statistical analysis. To compare proportions between samples, Fisher’s exact
test was performed using SPSS. Sample size was always nZ50. The only exception
occurred with calculation of the proportion of cells exhibiting centrosome declustering
(the percent of cells with declustered centrosomes out of all cells with CA at each
time point), as the number of cells with CA was typically o50. In all cases, results
were considered significant if Po0.05. To perform regression using proportions, beta
regression was used as described by Ferrari and Cribari-Neto41 using MATLAB.
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